These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 30804948)
61. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939 [TBL] [Abstract][Full Text] [Related]
62. Differential T cell subsets and cytokine profile between steady-state and G-CSF-primed bone marrow and its association with graft-versus-host disease. León-Rodríguez E; Rivera-Franco MM; Gómez-Martín D; Romo-Tena J; Juárez-Vega G; Merayo-Chalico J; Alcocer-Varela J Leuk Res; 2017 Dec; 63():47-52. PubMed ID: 29101827 [TBL] [Abstract][Full Text] [Related]
63. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958 [TBL] [Abstract][Full Text] [Related]
64. Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Kielsen K; Enevold C; Heilmann C; Sengeløv H; Pedersen AE; Ryder LP; Müller K Front Immunol; 2018; 9():109. PubMed ID: 29456530 [TBL] [Abstract][Full Text] [Related]
65. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300 [TBL] [Abstract][Full Text] [Related]
66. [Application of ricin-immunotoxin mediated T cell depletion to allogeneic hematopoietic stem cell transplantation]. Lai YY; Guo NL; Huang XJ; Xu LP; Chen H; Wang SQ; Zheng HY; Li Y; Shen BF; Lu DP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):270-3. PubMed ID: 15228648 [TBL] [Abstract][Full Text] [Related]
67. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376 [TBL] [Abstract][Full Text] [Related]
68. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis. Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586 [TBL] [Abstract][Full Text] [Related]
69. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia--a single-center experience. Wang H; Wang Z; Zheng X; Ding L; Zhu L; Yan H; Guo Z Cytotherapy; 2013 Sep; 15(9):1118-25. PubMed ID: 23806238 [TBL] [Abstract][Full Text] [Related]
70. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation. Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H Front Immunol; 2020; 11():558143. PubMed ID: 33178187 [TBL] [Abstract][Full Text] [Related]
71. Clinical factors influencing T-cell receptor excision circle (TRECs) counts following allogeneic stem cell transplantation in adults. Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Montserrat E Transpl Immunol; 2006 Jun; 16(1):52-9. PubMed ID: 16701177 [TBL] [Abstract][Full Text] [Related]
72. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Teltschik HM; Heinzelmann F; Gruhn B; Feuchtinger T; Schlegel P; Schumm M; Kremens B; Müller I; Ebinger M; Schwarze CP; Ottinger H; Zips D; Handgretinger R; Lang P Br J Haematol; 2016 Oct; 175(1):115-22. PubMed ID: 27341180 [TBL] [Abstract][Full Text] [Related]
73. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Lang P; Teltschik HM; Feuchtinger T; Müller I; Pfeiffer M; Schumm M; Ebinger M; Schwarze CP; Gruhn B; Schrauder A; Albert MH; Greil J; Urban C; Handgretinger R Br J Haematol; 2014 Jun; 165(5):688-98. PubMed ID: 24588540 [TBL] [Abstract][Full Text] [Related]
74. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596 [TBL] [Abstract][Full Text] [Related]
75. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956 [TBL] [Abstract][Full Text] [Related]
76. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation. Hosokai R; Masuko M; Shibasaki Y; Saitoh A; Furukawa T; Imai C Biol Blood Marrow Transplant; 2017 Apr; 23(4):606-611. PubMed ID: 28042021 [TBL] [Abstract][Full Text] [Related]
77. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Min CK; Kim DW; Lee JW; Han CW; Min WS; Kim CC Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278 [TBL] [Abstract][Full Text] [Related]
78. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727 [TBL] [Abstract][Full Text] [Related]
79. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Perko R; Kang G; Sunkara A; Leung W; Thomas PG; Dallas MH Biol Blood Marrow Transplant; 2015 Jan; 21(1):130-6. PubMed ID: 25445640 [TBL] [Abstract][Full Text] [Related]
80. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases. Stenger EO; Chiang KY; Haight A; Qayed M; Kean L; Horan J Biol Blood Marrow Transplant; 2015 Oct; 21(10):1845-52. PubMed ID: 26095669 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]